PMID- 31315613
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20200225
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Jul 17
TI  - The relationship between non-alcoholic fatty liver and skeletal muscle mass to 
      visceral fat area ratio in women with type 2 diabetes.
PG  - 76
LID - 10.1186/s12902-019-0404-1 [doi]
LID - 76
AB  - BACKGROUND: Sarcopenic obesity, central obesity combined with decreased skeletal 
      muscle mass, is identified to be associated with metabolic syndrome and 
      cardiovascular diseases; however, its role in the occurrence of non-alcoholic 
      fatty liver disease (NAFLD) among patients with type 2 diabetes mellitus (T2DM) 
      remains unclear. Therefore, this study aimed to investigate the value of the 
      skeletal-to-visceral ratio (SVR) in the prediction of NAFLD in T2DM. METHODS: 
      T2DM patients (n = 445) were recruited into the current study. Hepatic steatosis 
      was diagnosed based on ultrasonic results, while skeletal muscle mass as well as 
      visceral fat area (VFA) was estimated based on bioimpedance analysis 
      measurements. RESULTS: NAFLD prevalence increased with the decreased SVR 
      tertiles: statistically significant differences were observed in the highest 
      tertiles (21.5% in men, and 30.4% in women) and the lowest tertiles (53.9% in men 
      and 60.0% in women) (both P < 0.01). The decreased SVR tertiles were 
      independently associated with the presence of NAFLD in female T2DM patients, with 
      the odds ratio (OR) of 3.43 and 2.31 in the lowest and middle tertiles, 
      respectively. Besides, the areas under the curve (AUC) for identifying NAFLD were 
      0.675 and 0.63 in men and women, respectively (P < 0.05). CONCLUSIONS: T2DM 
      patients who have lower SVR levels are associated with higher risks of developing 
      the NAFLD-related complications. Besides, SVR shows independent correlation with 
      NAFLD in female T2DM patients, suggesting that SVR may be a useful index to 
      predict the high risk of hepatic steatosis in T2DM.
FAU - Su, Xiaoyou
AU  - Su X
AD  - Diabetes Center and Department of Endocrinology, The Second Affiliated Hospital 
      and Yuying Children's Hospital of Wenzhou Medical University, Lucheng District 
      Wenzhou, Wenzhou, Zhejiang Province, People's Republic of China.
FAU - Xu, Jing
AU  - Xu J
AD  - Diabetes Center and Department of Endocrinology, The Second Affiliated Hospital 
      and Yuying Children's Hospital of Wenzhou Medical University, Lucheng District 
      Wenzhou, Wenzhou, Zhejiang Province, People's Republic of China.
FAU - Zheng, Chao
AU  - Zheng C
AUID- ORCID: 0000-0002-7629-7627
AD  - Diabetes Center and Department of Endocrinology, The Second Affiliated Hospital 
      and Yuying Children's Hospital of Wenzhou Medical University, Lucheng District 
      Wenzhou, Wenzhou, Zhejiang Province, People's Republic of China. 
      zhengchao_3@163.com.
LA  - eng
GR  - 81670777/National Natural Science Foundation of China/
GR  - WKJ-ZJ-1625/Key Medical Science and Technology Plan of Zhejiang Province/
GR  - H20150001/Wenzhou Science and Technology Bureau Public Welfare Science and 
      Technology Projects/
PT  - Journal Article
DEP - 20190717
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
SB  - IM
MH  - Adult
MH  - Aged
MH  - China/epidemiology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*physiopathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Insulin Resistance
MH  - Intra-Abdominal Fat/*physiopathology
MH  - Middle Aged
MH  - Muscle, Skeletal/*physiopathology
MH  - Non-alcoholic Fatty Liver Disease/*epidemiology/pathology
MH  - Obesity/*physiopathology
MH  - Prevalence
MH  - Prognosis
PMC - PMC6637487
OTO - NOTNLM
OT  - Non-alcoholic fatty liver
OT  - Skeletal muscle mass
OT  - Skeletal muscle mass to visceral fat area ratio
OT  - Type 2 diabetes
OT  - Visceral fat area
COIS- The authors declare that they have no competing interests.
EDAT- 2019/07/19 06:00
MHDA- 2020/01/07 06:00
PMCR- 2019/07/17
CRDT- 2019/07/19 06:00
PHST- 2019/02/16 00:00 [received]
PHST- 2019/07/10 00:00 [accepted]
PHST- 2019/07/19 06:00 [entrez]
PHST- 2019/07/19 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/07/17 00:00 [pmc-release]
AID - 10.1186/s12902-019-0404-1 [pii]
AID - 404 [pii]
AID - 10.1186/s12902-019-0404-1 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2019 Jul 17;19(1):76. doi: 10.1186/s12902-019-0404-1.